Peer-influenced content. Sources you trust. No registration required. This is HCN.
Clinical Advances in Hematology & Oncology
Adding niraparib to abiraterone prolonged radiographic progression-free survival in BRCA-mutant metastatic hormone-sensitive prostate cancer, with overall survival data still maturing.
Hematology/Oncology May 26th 2026
Cancer Therapy Advisor
These results suggest that PARP inhibition represents a potential treatment strategy in HRR-deficient advanced biliary tract cancer, including the potential platform to investigate novel combination treatment strategies as well as consideration for a more selective biomarker selection.
Gastroenterology September 15th 2025
Oncology Learning Network
The results of PROfound and PROpel underscore the importance of identifying the genomic characteristics of the patient and the cancer to guide the selection of the most appropriate treatment for a specific patient type.
Oncology, Medical April 29th 2025
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS